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EVALUATION OF SUCCESSFUL REHABILITATION TREATMENTS FOR 
OPIOID ADDICTION 
JYLA HICKS 
 
ABSTRACT 
 
The opioid epidemic in America and worldwide is growing leading to an 
increase in opioid addiction ultimately ending in overdose and death. The 
specific aim of this paper is to evaluate the different treatment methods that aid 
with opioid addiction. The main medicated-assisted treatments (MATs) that will 
be discussed are buprenorphine and methadone. In addition to these two MATs, 
behavioral therapy treatment will also be of focus as it is often paired with a 
MAT to obtain the best treatment outcome. This paper will evaluate multiple 
factors that define successful opioid addiction treatment and treatment 
outcomes. These factors may include patient characteristics, relapse time if 
applicable, and length of sobriety after treatment completion also with other 
aspects. 
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INTRODUCTION 
 
Opioids such as fentanyl, morphine, codeine and vicodin are all 
medications that are prescribed to aid with pain relief but are also highly 
addictive (Aronson et al., 2016). Physicians struggle daily when trying to make 
the decision of how to treat chronic pain while avoiding potential opioid 
addiction. For example, fentanyl, a synthetic opioid often used for chronic pain 
relief, is a great addition to treatment when administered properly at the correct 
dosage (Aronson et al., 2016). Problems often arise for the reason that fentanyl 
dosages are often illegally tampered with due to the potency of fentanyl which is 
1000 times more powerful than traditional opioids such as pethidine (Aronson et 
al., 2016). The grave increase in potency compared to other opioid medications 
often allows fentanyl to be easily abused which leads to addiction, overdose and 
ultimately death. 
The number of opioid related overdoses and the mortality rate of those 
addicted to opioids is increasing at an fast rate. According to the Center for 
Disease Control (CDC) National Center for Health Statistics (NCHS), the average 
death rate per 100,000 people in 2014 was 14.7 compared to 9.4 in 2004 
(CDC/NCHS, 2017). The progressive growth in opioid abuse and opioid related 
overdoses is a serious everyday problem in the United States with over 115 
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people dying daily from drug overdoses (CDC/NCHS, 2017). The increasing 
number of opioid related deaths has caused an urgency to find successful 
remediation treatments for this relativity new epidemic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Number of Drug Related Deaths Involving Opioid Analgesics and 
Heroin Data based off deaths in the United States in 2004 spanning to 2014 (Chen 
et al., 2014). 
 
Opioid addiction not only comes with associated health risks and effects 
but also lends to economic problems such as increased health care costs and 
societal costs (Lipman & Webster, 2015). The estimated cost of drug addiction 
treatment and preventative addiction services in the United States totaled to 4.5 
billion dollars over ten years ago (Mart et al., 2005). This astounding dollar 
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amount becomes more eye-opening knowing that the 4.5 billion dollars only 
covered 3% of the total societal cost (Mart et al., 2005). Table 1 displays the 
associated health care cost increase as a result of patients newly diagnosed with 
opioid addiction. 
 
Table 1. Increase in Health Insurance Cost Due to Opioid Addiction 
Data based off Medicare and Medicaid Databases (Florence et al., 2013) 
 
 
Insurance Type N Appraised Cumulative Effects 
(95% Confidence Interval) 
Medicare 6,917 $17, 052 ($13,472, $20,632) 
Medicaid 30,454 $13,743 ($12, 341, $15,145) 
 
 
Societal costs are not exclusive to dollar amounts but should also include 
the negative experiences and stress the family and friends of those abusing 
opioids deal with. Consequences that the families may have to deal with can 
include shame, miscarried expressions of anger, and an overall negative 
environment that involves the drug abuser (Center for Substance Abuse 
Treatment, 2004). Finding the most successful treatment option for opioid abuse 
will lead to an overall greater and more efficient way to treat addiction. The 
improvement in treatment success will create wide stretch rewards such as 
decreases in crime rates, lowered economic and societal costs, and improved 
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global health due to a decrease in infections such as human immunodeficiency 
virus (HIV) and hepatitis (Schwartz et al., 2008). The three treatments that will be 
discussed in depth are behavior therapy, buprenorphine, and methadone. 
Behavioral Therapy 
 
According to the Controlled Substance Act put in place under President 
Richard Nixon, physicians are mandated to offer or refer behavioral therapy 
treatment when treating opioid dependence with MATs such as buprenorphine 
and methadone (Controlled Substance Act, 1996). Although this requirement has 
been put in place, few studies on what behavioral therapy treatment type is most 
successfully paired with MATs have been examined. The National Institute on 
Drug Abuse (NIDA) has worked to tackle this deficit in knowledge and expand 
the development of behavioral therapies by creating a scientific framework that 
includes three stages to guide the expansion of new behavioral therapies (Onken 
et al., 1996). 
Stage one is a preliminary period that sets the basis for creating an entirely 
new behavioral therapy or making significant changes to a preexisting therapy 
(Onken et al., 1996). Stage one can be compared to brainstorming while 
completing investigative research that supports the need to make alterations to 
existing therapies or to create an entirely new field. During stage two, 
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effectiveness testing is taking place in order to evaluate the therapies and ensure 
that they show promise for use in the future (Onken et al., 1996). Stage two can 
be seen as the most important stage because it will show the efficacy of the 
treatment but stage three is vital to show that the proposed study will be 
effective in the field and not only in a controlled experimental setting 
(Rounsaville et al., 2001). 
Methadone 
 
Methadone is often used by physicians to relieve chronic pain or to assist 
with opioid abuse detoxification and rehabilitation (Grissinger, 2011). 
Methadone is often selected as a treatment option due to its long-lasting effects 
which means fewer doses are needed to have pain relief or suppress drug 
cravings (Brown, 2004). While taking methadone, one may experience side effects 
that may seem monogamous with opioid abuse such as dizziness, vomiting, and 
fatigue (Macey et al., 2013). Death as a result of a methadone overdose is possible 
due to the depressing physiological nature of the drug so dosage is vital to 
maintain at a healthy amount to decrease risks (Chou et al., 2015). 
Methadone maintenance therapy (MMT) is a treatment used specifically 
to combat illicit drug use (Mattick et al., 2009). Treatment usually takes place at 
an outpatient clinic where the medication is given by a licensed health provider 
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(Mattick et al., 2009). The length of time persons will be on methadone treatment 
varies and depends on multiple factors (Joseph et al., 2000). Some of the factors 
determining the duration of MMT is the length of drug use before methadone 
treatment starts, the method of abuse such as intranasal or intravenous and also 
the type of drugs abused (Joseph et al., 2000). MMT can be an excellent treatment 
option when prescribed and used correctly, if not, abuse of methadone can lead 
to physical dependence similar to illicit drugs (Joseph et al., 2000). 
Buprenorphine 
 
 
Buprenorphine is a medication used in the treatment of opioid addiction 
that holds similar organic molecular structure and activity to morphine and 
fentanyl (Cowan et al., 1977). Figure 4 shows examples of opioid analgesics 
including buprenorphine which are similar to morphine and fentanyl, two 
commonly abused drugs (Martin et al., 2016) and also methadone which will be 
discussed in greater detail. 
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Figure 2. Examples of Opioid Analgesics used for Moderate to Severe Pain 
Treatment (Martin et al., 2016). 
 
The three receptors in the brain that opioids and endogenous peptides 
exert their pharmacological actions on are kappa, mu, and delta (Raynor et al., 
1994). Once activated, these receptors can activate an array of behavioral 
physiological changes that include autonomic functions such as heart rate and 
respiration, but also other bodily changes like mood and pain awareness (Raynor 
et al., 1994). The physiological and behavioral effect of the binding molecule on 
the receptor depends on its affinity and efficacy (Khroyan et al., 2015). The mu 
receptor when activated causes constipation, slowed respiration and feelings of 
euphoria which is the key effect that leads to potential abuse (Khroyan et al., 
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2015). By contrast, the kappa receptor when activated reduces constipation, 
increases respiration and causes feelings of dysphoria instead of euphoria 
(Khroyan et al., 2015). 
Once abused, drugs like morphine and fentanyl can easily lead to death 
being that they bind with extremely high efficacy to the mu receptors which will 
cause a slowness of breath and potentially lead to death. Buprenorphine also has 
a partial high affinity for the mu receptor just like morphine and fentanyl but 
also is an antagonist to the kappa and delta receptors which will combat those 
deadly side effects of over stimulating the mu receptors (Khroyan et al., 2015). 
Buprenorphine is a great alternative to morphine due to its lipophilic quality and 
ability to last for a substantial amount of time in the body which helps fight 
opioid addiction (Mello et al., 1993). MAT with buprenorphine will be examined 
to look at how successful it is with opioid dependence rehabilitation. 
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PUBLISHED STUDIES 
 
 
The behavioral therapy treatments used to rehab drug abuse and 
dependence that were successful in stage two of the scientific framework to 
expand behavioral therapies set by the NIDA include family/community 
approaches, motivational interviewing, contingency management, and cognitive 
behavior approaches (Onken et al., 1996). These behavioral therapy treatments 
are seen to be specifically successful when dealing with opioids and other drugs 
such as cocaine and marijuana dependence (Onken et al., 1996). 
Contingency Management 
 
The behavioral therapy treatment coined contingency management is 
often used in combination with prize reinforcement as treatment for opioid 
addiction (Lewis, 2009). Contingency management is constructed on the theories 
of B.F. Skinner’s operant conditioning using the model to reinforce positive 
behaviors with a reward (Lewis, 2009). In the case of contingency managed 
opioid treatment, the positive behavior would be abstaining from drug use and 
being monitored by drug tests while the reward could be of monetary value or a 
strongly desired item by the opioid-dependent patient. The goal of this treatment 
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is to reinforce the positive behavior so that the likelihood of it reoccurring is 
increased and the likelihood of relapse is decreased (Higgins, 1997). 
Granted that MATs for opioid dependency combined with behavioral 
therapy have seen to be effective, the type of behavioral therapy and MAT used 
may skew effectiveness results and are still under research. For example, Warren 
Bickel and colleagues found that adding behavioral treatments such as 
contingency management with prize reinforcement and the community/ family 
therapy approach with MAT using buprenorphine increased successful 
rehabilitation outcomes rather than no combined behavioral therapy treatment at 
all (Bickel et al., 1997). However, Ling and colleagues compared two different 
behavioral therapy treatments, cognitive behavioral therapy, and contingency 
management with MAT using buprenorphine and found no significant 
difference in opioid use when buprenorphine is not combined with behavioral 
therapy (Ling et al., 2013). Both studies compared behavioral therapy combined 
with MATs with buprenorphine but received different results that could be 
attributed to various external variables and will be further examined. 
The effects of adding behavioral therapy treatment to opioid 
detoxification and rehabilitation was further researched by Bickel and colleagues 
using thirty-nine opioid dependent participants (Bickel et al., 1997). Table 2 and 
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Table 3 display the participant characteristics and attributes that were surveyed 
before starting the trials. The participants were randomly recruited over a 16- 
month period by strategies such as newspaper and media postings. 
Table 2. Participant Characteristics Including Demographics and Opioid Use 
Measuring Contingency Management and Buprenorphine Treatment 
Data based off pretrial interview responses (Bickel et al., 1997) 
 
 % or M ± SD 
Characteristic Behavioral Group 
 
(N=19) 
Standard Group (N=20) 
Demographics 
White 100 95 
Male 63 65 
Never married 42 40 
High school education 95 85 
Employed 37 45 
Age (years) 33.6 ±7.3 34.6 ±8.0 
Opioid Use 
Prior treatment 79 80 
Years of regular use 8.8 ± 7.1 11.4 ± 7.4 
Age of first use 20.4 ± 4.7 21.0 ± 3.9 
Dollars spent weekly 225 ± 266 338 ± 310 
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Table 3. Participant Characteristics Including Opioid Use Preferred Route 
Measuring Contingency Management and Buprenorphine Treatment 
Data based off pretrial interview responses (Bickel et al., 1997) 
 
 % or M ± SD 
Characteristic Behavioral Group 
 
(N=19) 
Standard Group (N=20) 
Opioid Use – Preferred Route 
Intravenous 63 65 
Oral 21 20 
Intranasal 16 15 
 
 
During the one-week period of treatment, patients were assigned to either 
the standard or the behavioral group using minimum likelihood allocation based 
on certain characteristics (Bickel et al., 1997). Treatment was administered by 
master-level counselors trained specifically for the study and overseen by two 
higher level psychologists that reviewed each patient’s status on a weekly basis 
to review progress (Bickel et al., 1997). The behavioral therapy treatment used 
was contingency management combined with community support. Contingency 
management with prize reinforcement was maintained using a voucher system 
that rewarded patients monetarily based on clean urine samples (Bickel et al., 
1997). 
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The voucher system used by Bickel directly translated to points that were 
worth dollars and patients received the cash equivalent in services such as 
dinner at restaurants or phone amenities (Bickel et al., 1997). Each urine sample 
negative for drugs was worth 29 points that translated to $0.125 a point or $3.63 
for each sample. Every drug free urine sample provided by the patient earned a 
point value increase by one. For example, the second negative urine sample 
would earn the patient 30 points and the third negative urine sample would earn 
the patient 31 points. After three consecutive negative urine samples the patient 
earns an additional $5 award. The trial was a 26-week long period with the first 
week used as a baseline to establish correct buprenorphine doses and the last 
two weeks were void of voucher rewards to wean the patients off the reward 
system. Altogether, during the 23-week voucher trial period the patient could 
earn up to $658.38 (Bickel et al., 1997). 
The results displayed in figure 2 show that there is a better overall 
outcome with the behavioral therapy treatment as opposed to the standard 
treatment with no therapy (Bickel et al., 1997). The percentage of patients that 
completed treatment in the behavioral therapy treatment group was more than 
double the standard treatment group at fifty-three percent versus twenty percent 
(Bickel et al., 1997). 
14  
 
 
 
 
Figure 3. Percentage of Patients Retained in Treatment at the End of Each 
Treatment Week. The dashed vertical line before Week 24 indicates the start of 
the placebo period as a function of treatment week. Closed squares indicate 
behavioral treatment; open squares indicate standard treatment (Bickel et al., 
1997). 
 
According to the trial standards, continuous abstinence occurs when a 
patient provides consecutive opioid free urine samples (Bickel et al., 1997). 
Results from the trial showed that patients in the behavioral therapy treatment 
group displayed continuous abstinence at a greater rate than the standard 
treatment group as shown in Figure 3 (Bickel et al., 1997). During treatment 
weeks 4, 8, 12, and 16, the behavioral therapy treatment group had a continuous 
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abstinence patient level of 68, 47, 26, and 11 percent compared to the standard 
treatment group where percentages were 55, 15, 5, and 0 (Bickel et al., 1997). 
Figure 4. Percentage of Patients Attaining Continuous Opioid Abstinence. 
Dark bar indicates behavioral treatment; light bar indicates standard treatment 
Bickel et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cognitive Behavioral Therapy 
 
Cognitive behavioral therapy treatment has been used in the past not only 
to aid with psychological disorders (Ammar & Khoury, 2014), but also substance 
abuse disorders with drugs such as opioids and cocaine (Iwano et al., 2013). 
Substance abuse treatment using cognitive behavioral therapy originally 
stemmed from cognitive behavioral therapy treatments developed for 
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psychological disorders such as depression and anxiety (Meichenbaum, 1995) but 
was later applied to substance abuse disorders (Marlatt & Gordon, 1985). 
Cognitive behavioral therapy can take place in a group or individual counseling 
session that focuses primarily on behavior changes and skills to help make the 
desired transformation happen (Ling et al., 2013). According to the American 
Psychiatric Association (APA) there are two key components of cognitive 
behavioral therapy when dealing with substance abuse disorders which includes: 
“1) an emphasis on functional analysis of drug use-that is, understanding 
drug use with respect to its antecedents and consequences- and 2) 
emphasis on skills training” (Carroll et al., 2004). 
 
The cognitive behavioral therapy approach focuses on the patient directly 
to foster the skills needed for a successful rehabilitation to obtain sobriety and 
avoid relapse. Examples of skills needed for a successful rehabilitation from 
drugs includes actively self-monitoring thoughts and behaviors that take place 
during high-risk drug usage, not only understanding drug cravings but also 
being knowledgeable of healthy ways to cope with them, and most importantly 
having the strength to strongly refuse drugs or drug exposure (Carroll et al., 
2004). Cognitive behavioral therapists work with patients to apply these skills 
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not only to substance abuse related issues but also to different situations that 
could be beneficial to the patient in their everyday life (Carroll et al., 2004). 
The evaluation of successful rehabilitation treatments using cognitive 
behavior therapy combined with buprenorphine was completed by Moore and 
colleagues (Moore et al., 2016). The study length was 26 weeks and included 48 
patients addicted to opioid medication with their characteristics being shown in 
Tables 4 and 5. 
Table 4. Participant Characteristics Including Demographics and Opioid Use 
Measuring Cognitive Behavioral Therapy and Buprenorphine Treatment 
Data based pretrial evaluations (Moore et al., 2016) 
 
Characteristic Cognitive Behavioral Treatment (N=48) 
% White (n) 94% (45) 
% Male (n) 71% (34) 
% Never married (n) 62% (30) 
% High school education (n) 87% (40) 
% Full-time Employed (n) 51% (24) 
Age (years), mean 32.4 
Opioid Use 
% Prior attempted detoxification 24% (11) 
% Prior treatment (not detox) 49% (22) 
Years of opioid use, mean 6.6 
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Table 5. Participant Characteristics Including Opioid Use Preferred Route 
Measuring Cognitive Behavioral Therapy and Buprenorphine Treatment 
Data based pretrial evaluations (Moore et al., 2016) 
 
 % 
Characteristic Cognitive Behavioral Treatment (N=48) 
Opioid Use – Current route of administration 
% Intravenous (n) 2% (1) 
% Oral (n) 37% (17) 
% Intranasal (n) 61% (28) 
 
 
During the 26-week study period, opioid use was assessed by patient self- 
report and weekly urine screenings. The patient’s addiction severity index was 
also measured monthly by a trained research technician. The addiction severity 
index is a structured interview evaluation to identify and record potential high 
risk category responses that affect substance abuse patients (McLellan et al., 
1992). At the end of the trial, all samples were totaled and consecutive abstinence 
from opioids was based on self-reporting but verified by the urine screening 
results. Treatment completion was measured by retention variables that defined 
it as completing the trial up until week 24 and not being withdrawn due to 
factors that include missing more than three physician sessions or missing 
required medications for more than one week. Completion included 24 weeks 
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since the trial included a 2-week induction/stabilization period and then 24 
weeks of maintenance. 
The cognitive behavioral therapy trial was randomized into two groups so 
that patients would either be in a primary-care physician management group or 
in a physician management group with cognitive behavioral therapy. Both 
groups received the buprenorphine medication with an individualized dose 
depending on the needs of the patient that included distress or continued opioid 
use. The physician managed group without cognitive behavioral therapy met for 
15 to 20 minutes and were run by internal medicine physicians who were not 
trained in cognitive behavioral therapy methods. The internal medicine 
physicians also administered the buprenorphine medication. Included in the 
sessions were self-report discussions, urine screenings, and brief discussions on 
ways to avoid opioid use. 
Physician managed sessions occurred weekly for the beginning of the trial 
then after two weeks, the sessions occurred bi-weekly and at 6 weeks, the trial 
sessions became monthly. The cognitive behavioral therapy and buprenorphine 
treatment trial group met every week for 12 weeks with 50-minute sessions. Each 
session was guided by a clinician that was master or doctorate level certified. 
Every clinician in the behavioral therapy treatment group was trained 
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specifically in behavioral therapy and also supervised patients similar to the 
internal medicine physicians in the physician managed group. 
Table 6. Treatment Outcomes of Opioid Use Groups Depending on the 
Addition of Cognitive Behavioral Therapy (Moore et al., 2016) 
 
 Physician Management + 
Cognitive Behavioral 
Therapy (n = 23) 
Physician 
Management 
(n = 26) 
Completed treatment 48% (11) 54% (14) 
Weeks in treatment 19.4 (6.9) 19.4 (6.2) 
Number of missing urine 
 
screens 
0.78 (1.17) 0.64 (0.95) 
Number of urines negative 
 
for opioids 
12.0 (8.4) 9.7 (8.1) 
Longest consecutive 
weeks of opioid 
abstinence 
8.9 (7.8) 5.7 (6.5) 
Number of urines negative 
 
for all drugs 
7.6 (7.9) 3.7 (5.4) 
 
 
The results in Table 6 show that overall, physician managed treatment and 
cognitive behavioral therapy had a greater success rate at rehabilitation than 
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physician management alone. The physician managed group had a higher 
number of patients complete the treatment, but that is the only advantage when 
compared to the cognitive behavioral therapy treatment group. 
Buprenorphine and Methadone 
 
 
A study was completed to compare MAT with buprenorphine to MAT 
with methadone (ref). Participants included a total of 1,269 patients recruited 
from opioid treatment programs. The clinical profiles including demographics 
are seen in table seven and obtained through health surveys and a 4-week self- 
report screening period to provide current drug history summaries. Each 
participant was randomized with 740 participants in the buprenorphine 
treatment group and 529 participants in the methadone treatment group. The 
discrepancy in treatment group sizes is a consequence of patient dropout and 
rare treatment group changes as a result of pregnancy. 
The study was 32 weeks long with a minimum of 24 weeks on medication 
and the last 8 weeks being variable for tapered medication or referral to a clinic 
to continue treatment. Medication was distributed daily except for Sundays or 
holidays where patients were issued a take home dose by clinic physicians. The 
initial study required that participants abstain from opioids for 12 to 24 hours so 
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they would ideally be in the early stages of withdrawal where the physician 
could individually evaluate and prescribe the correct dose for each patient. 
Opioid usage was monitored weekly with drug screenings while self-report data 
was evaluated every 4 weeks. The drug screenings were in the form of a urine 
sample that was monitored for temperature and strip tested for illicit drugs. 
Table 7. Clinical Profiles at Baseline of MAT with Buprenorphine and 
Methadone (Hser et al., 2014) 
 
 Buprenorphine 
 
(n=738) 
Methadone 
 
(n=529) 
Total 
 
(n=1267) 
Age, mean (SD) 37.5 (11.2) 37.3 (10.9) 37.4 (11.1) 
Female gender, % 32.0 32.1 32.0 
White, % 69.4 74.1 71.4 
Days using opioids 
 
in past 30 days 
26.8 26.7 26.8 
Cocaine-positive 
 
UDS, % 
34.0 42.0 37.3 
Amphetamine- 
 
positive UDS, % 
8.7 9.5 9.0 
Drug injection in 
 
past 30 days, % 
68.3 69.3 68.7 
SD = standard deviation, UDS = urine drug screen 
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The profiles in Table 7 show that both MAT groups with buprenorphine 
and methadone were similar. The overall general profile of a participant in this 
study was an early middle-aged white male. The study also included other 
ethnicities such as African American at 9% and Hispanic at 12%. Some 
participants in both treatment groups tested positive for drugs other than opioids 
and commented on alcohol use at mean of approximately 27%. 
Table 8. Dropout reasons (%) of MAT with Buprenorphine and Methadone 
(Hser et al., 2014) 
 
 Buprenorphine 
 
(n=738) 
Methadone 
 
(n=529) 
Total 
 
(n=1267) 
Dropout reasons, % N = 398 N = 137 N = 535 
Missed 14 or more days 63.1 68.6 64.5 
No longer wish to 
 
participate 
25.6 12.4 22.2 
Administrative 
 
discharged 
3.5 4.4 3.7 
Not medically approved 3.8 3.7 3.7 
Other reasons 
 
(incarceration, moved) 
4.0 11.0 5.8 
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Table 9. Treatment Completion (%) of MAT with Buprenorphine and 
Methadone (Hser et al., 2014) 
 
 Buprenorphine 
 
(n=738) 
Methadone 
 
(n=529) 
Total 
 
(n=1267) 
Dropout during the first 30 
 
days of treatment, % 
24.8 8.3 17.9 
Completed the 
 
24-week trial, % 
46.1 74.1 57.8 
Retention (days in treatment), 
 
mean (SD) 
103.8 (66.9) 141.3 (50.8) 119.4 (63.5) 
Participants who stayed in 
 
treatment more than 30 days 
N = 555 N = 529 N = 1040 
Competed the 
 
24-week trial, % 
61.3 80.8 70.4 
Retention (days in treatment), 
 
mean (SD) 
133.3 (49.2) 152.8 (34.8) 142.2 (44.1) 
SD = standard deviation 
Shown in Table 9, during the first 30 days of treatment, the dropout rate 
for the buprenorphine treatment group was about three times higher at 24.8% 
versus 8.3% for the methadone treatment group. After the first 30 days, the 
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buprenorphine treatment group still had a lower completion percentage at 61.3% 
versus 80.8% for the methadone treatment group. Table 8 shows a similar 
percentage for 14 or more days missed at 63.1% for the buprenorphine treatment 
group and 68.6% for the methadone treatment group. When considering the 
other evaluated sections, researchers found that the majority of participants that 
dropped out of the buprenorphine treatment group did so because they no 
longer wished to participate in the study. 
During Hser’s study with buprenorphine and methadone, doses were 
increased as the trial progressed to accommodate for any changes needed by the 
patient and to test the hypothesis that higher doses would reduce opioid 
cravings and decrease potential relapse occurrences (Hser et el., 2014). Figure 5 
displays the results of urine tests compared to the dosage over the 24-week trial 
period. The results show that increase in both buprenorphine and methadone 
doses decrease positive opioid urine test with buprenorphine having a greater 
influence on the decrease compared to methadone. Also, the plotted line graph in 
Figure 5 shows that opioid use was much lower in the buprenorphine treatment 
groups during the first ten weeks then eventually leveled out to similar levels 
with the methadone treatment group. 
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Figure 5. Average Dose and Positive Opiate Urine Test Across Weeks by 
Treatment Group (n=1,267) (Hser et el., 2014). 
 
Hser and colleagues completed another study examining the long-term 
outcomes of using buprenorphine versus methadone MAT at multiple treatment 
programs across the United States (ref). The initial study began with 1,269 
precipitants randomized to the buprenorphine treatment group (n=740) or the 
methadone treatment group (n=529). Due to several different variables across 
treatment sites only a total of 795 participants were interviewed for a follow up 2 
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to 8 years post study. Displayed in Table 10 are clinical profiles for all 
participants in the study. 
Table 10. Clinical Profiles of Interviewed Samples at Baseline of Long- Term 
MAT of Buprenorphine versus Methadone (Hser et al., 2016). 
 
 Randomized to 
buprenorphine 
(n=464) 
Randomized 
to methadone 
(n=331) 
Total 
(n=795) 
Age at baseline, mean (SD) 37.4 (11.1) 37.4 (11.3) 37.4 (11.2) 
Female gender, % 32.8 35.9 34.1 
White, % 72.0 73.4 72.6 
Days using opioids in past 30 
days 
26.8 26.7 26.8 
In past 30 days, self-report use 
of Cocaine, % 
30.2 37.2 33.1 
In past 30 days, self-report use 
 
of Amphetamine, % 
7.3 7.3 7.3 
SD = standard deviation 
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For the follow up interviews, participants returned to their original clinic 
location where face-to-face interviews were held by research staff. The interviews 
lasted approximately 1 to 2 hours and, while at the clinic, participants were paid 
not only for the face-to-face interview but also to submit urine and saliva  
samples that were tested for drugs and HIV. The results of the follow up 
interviews, test samples, and self-reports given at the interview are shown in 
Table 11. The class of opiates/analgesics in Table 11 include prescription opioids 
such as oxycodone, and hydrocodone. 
Table 11. Current Heroin and Opiate Use at the Follow-up Interview 
(Hser et al., 2016). 
 
 Randomized to 
buprenorphine 
(n=464) 
Randomized to 
methadone 
(n=331) 
Total 
(n=795) 
Heroin use in the past 30 days (%) 
0 63.2 69.5 65.8 
1-5 12.6 11.8 12.2 
6-20 8.9 8.1 8.6 
21-30 15.4 10.6 13.4 
Mean (SD) 5.8 (10.5) 4.4 (9.3) 5.2 (10.1) 
SD = standard deviation 
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Table 11. Current Heroin and Opiate Use at the Follow-up Interview Cont. 
(Hser et al., 2016). 
 
 Randomized to 
buprenorphine 
(n=464) 
Randomized 
to 
methadone 
(n=331) 
Total 
(n=795) 
Use of other opiates/analgesics in the past 30 days (%) 
0 77.9 85.2 81.0 
1-5 10.6 8.5 9.7 
6-20 5.2 2.4 4.0 
21-30 6.3 3.9 5.3 
Mean (SD) 2.7 (7.4) 1.6 (5.9) 2.2 (6.9) 
Positive urine test on 
 
heroin or opiate use (%) 
42.8 31.7 38.1 
Used heroin or opiates as 
indicated by urine test or 
self-report (%) 
50.9 41.1 46.8 
SD = standard deviation 
 
Not included in the tables are the mortality rates which totaled 23 deaths 
in the buprenorphine treatment group and 26 deaths in the methadone treatment 
group. The buprenorphine treatment group had a significantly greater number of 
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patients that tested positive for heroin at the follow-up interview with 42.8% 
compared to the methadone treatment group at 31.7%. The trial accounted for 
treatment retention, and status as well, which showed that patients randomized 
to methadone treatment spent more time in treatment at 149.4 days in 
comparison to the buprenorphine treatment group at 111.4 days. Also noted is 
that 3.7% of participants in the buprenorphine treatment group and 4.9% in the 
methadone treatment group choose to continue a treatment option without 
opioid medications after the trial was complete. It is significant to note that both 
treatment groups experienced a decline in participation over the period of the 
trial but the methadone treatment group appeared to retain a greater number of 
patients. 
When making the decision to choose a treatment plan for a disease that is 
heavily patient oriented, the patients’ willingness to abide by the treatment plan 
is vital to its success. A study completed in Baltimore City examined the patient 
perspectives on MATs deciding between buprenorphine or methadone when 
equal access to both is provided (ref). This study was contained in another larger 
clinical trial where patients had the choice of which MAT to receive and 
ultimately choose buprenorphine. The study included 80 participants, whose 
patient characteristics can be seen in Table 12. The majority of the participants, at 
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85%, previously received buprenorphine off the street and 68% of the 
participants in the study were in a previous opioid agonist treatment. 
Table 12. Participant Characteristics Involved in Choosing Buprenorphine 
over Methadone (Gryczynski et al., 2013) 
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Information was collected by research assistants prior to the beginning of 
the larger randomized clinical study to determine why buprenorphine was 
selected as the MAT of choice instead of methadone. Unlike other studies 
examined in this paper, the exclusion criteria were less stringent, only excluding 
pregnant women or participants with significant cognitive disabilities. 
The study began with research assistants asking three open-ended 
questions and the first two were asked without any mention of methadone to 
avoid possible manipulation. The three open-ended questions were: 
“(1) why did you decide to get treatment with buprenorphine?; a follow- 
up probe of (2) what was the single most important reason that you 
entered buprenorphine treatment?; and (3) why did you choose 
buprenorphine and not methadone treatment?” (Gryczynski et al., 2013). 
 
After the open-ended questions, research assistants asked a series of 16 
structured questions pertaining to choosing buprenorphine over methadone. The 
16 questions were created specifically to address the contrasting qualities 
between the two MATs which included  the  pharmacology, route of 
consumption, and how the MATs are viewed in society. The answer choices for 
the questions were: not at all important, a little important, or very important, and the 
results to the questions can be seen in Table 13. 
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For the 16 questions there were six themes which included (1) Treatment 
Readiness (2) Withdrawal Avoidance (3) Normalcy (4) Preference over 
Methadone (5) Negative Effects of Methadone and (6) Sources of Knowledge. For 
theme one, treatment readiness, the discussion was heavily weighed on the 
patient and their reasons for wanting to enter treatment. Most answers were 
geared toward the notion of becoming healthy and drug free again rather than 
specifically wanting to seek treatment for buprenorphine. Theme two, 
withdrawal avoidance, was a big selling point for patients on why they choose 
buprenorphine over methadone because they felt as if the symptoms would be 
milder but also effective for suppressing cravings. Theme three, normalcy, was 
about the selection of buprenorphine over methadone due to the non-sedating 
effects which allowed patients to proceed with their daily routines. 
Theme four, preference over methadone, touched on the overall notion 
that patients where choosing buprenorphine as a direct alternative to methadone 
with 52.5% unsolicitedly comparing the two MATs. Also with this theme, 
patients seemed to view buprenorphine as a less serious medication in 
comparison to methadone. Statements were made such as, “I see people do the 
methadone and it's nasty and it puts me to sleep.... Taking the buprenorphine is 
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like taking a vitamin, so it's strengthening me.” which represents the negative 
stigma methadone has in the drug treatment community (ref) 
Overall theme four, preference over methadone, had a lot to do with the 
pharmacology of the two treatments and the preferred being whichever 
treatment allowed the least negative symptoms. Theme five, negative effects of 
methadone, spoke about the detrimental physical effects that occur as a result of 
taking methadone such as deterioration of bones and teeth, gastrointestinal 
problems, alterations in physical appearance and the possible increase in 
cravings for drugs other than opioids. Theme six, sources of knowledge, focused 
on where patients received their knowledge about buprenorphine. About one- 
third of the patients stated that they learned about buprenorphine in a non- 
clinical setting. Many patients seen buprenorphine in their communities and that 
first-hand experience drove them to receive formal treatment that was prescribed 
by a physician. 
During this study it was noted that the personal experience of use of 
buprenorphine either directly or indirectly was very important to treatment choice 
by 73.8% of clinical patients and of little importance to 11.3% of patients. Along 
with personal experience, participants were extremely concerned with the 
possible physical effects that could occur due to the MATs so withdrawal 
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intensity was very important to 77.5% of patients. Those participants that were 
previously in MAT with methadone seemed to respond less conservatively than 
other participants who had not gone through methadone treatments using more 
very important statements when choosing buprenorphine over methadone. 
Table 13. Responses to Structured Questions from Participant Involved in 
Choosing Buprenorphine over Methadone (Gryczynski et al., 2013) 
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DISCUSSION 
 
 
The findings in the study of adding behavioral therapy treatment, 
specifically contingency management, to opioid detoxification with 
buprenorphine conclude that behavioral therapy treatment improves 
detoxification and rehabilitation success when compared to standard care (Bickel 
et al., 1997). The retention rates as shown in Figure 2 are significant because they 
indicate that the number of patients remaining in treatment with behavioral 
therapy was doubled compared to the standard therapy group. During treatment 
weeks the opioid abstinent patient numbers were greater in the behavioral 
therapy treatment group compared to the standard treatment group. When 
looking at the patient characteristics in Table 2, the demographics were 
extremely similar in both treatment groups which decreases many possible 
confounding variables. 
A point of interest to note is that although the master-level counselors in 
this study were trained in contingency management therapy and overseen by 
higher level psychologists, they were used in both treatment groups. 
Unknowingly, the counselors could have been biased to the standard group with 
the assumed expectation that they would underperform and fail at sobriety 
without the behavioral therapy treatment which would cause them to 
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underachieve at a greater rate than normal. Another noteworthy aspect to the 
Bickel trial is that both groups had relatively small sample sizes with around 20 
patents in each group. Although the results are still valid, the question of 
generalization of the study results become an issue. 
Another study examining behavioral therapy combined with MATs by 
Moore focused on cognitive behavioral therapy specifically (ref). Along with the 
study on MAT and contingency management, the patient demographics in this 
study included a majority of middle-aged white men. 
Research found that patients who received cognitive behavioral therapy in 
addition to their physician managed MAT with buprenorphine had better 
outcomes than those in the study that were only subjected to physician managed 
MAT with buprenorphine (Moore et al., 2016). The information in Table 6 shows 
that a greater percentage of patients in the physician managed group completed 
treatment and that patients in both groups completed a similar number of weeks 
in treatment but the results can be seen as masked due to the difference in 
treatment group size that manipulates the data percentages. 
When examining the results further, data in Table 6 shows that patients in 
the physician managed group combined with cognitive behavioral therapy 
treatment had a greater number of urine samples negative for opioids and 
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negative for all drugs. Also, patients in the physician managed group combined 
with cognitive behavioral therapy treatment had the longest consecutive weeks 
abstinent from opioids when compared to the patients subjected only to 
physician management. Overall there seems to be an improvement in treatment 
outcomes when it comes to opioid rehabilitation that combines MATs and 
behavioral therapy treatment regardless of the behavioral treatment type. 
Now examining different types of MATs, buprenorphine and methadone 
were both reviewed in the clinical setting by Hser and colleagues (ref). The first 
study focused on treatment retention among patients randomized to 
buprenorphine compared to methadone. The treatment results were significant 
starting with the treatment dropout amount that included 398 patients in the 
buprenorphine treatment group compared to 137 patients in the methadone 
treatment group (Hser et el., 2014). Buprenorphine treatment had a greater 
dropout percentage at 24.8 compared to methadone which was 8.3 percent (Hser 
et el., 2014). This alarming difference should signal that the beginning weeks of 
treatment are critical for those on MAT with buprenorphine and additional 
measures may need to be put into place such as a behavioral therapy treatment 
option. 
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The patients that remined in the trial in the buprenorphine treatment 
group had a lower number of positive urine samples compared to the methadone 
treatment group during the beginning period of the trial. These results show that 
buprenorphine can be effective but retention focused methods need to be 
established in order to retain patients in rehab treatments. Again, the suggestion 
of implementing behavioral therapy treatment sessions would potentially help 
resolve the significant patient dropout rates. Hser also completed a second study 
comparing the long-term outcomes of buprenorphine and methadone treatment. 
Findings were similar to the previous study that compared buprenorphine 
and methadone. Both MATs were able to reduce the use of opioids in patients 
but at the follow-up it was clear that methadone was superior in receiving better 
results. During the initial treatment and also during the follow up, patients in the 
buprenorphine treat group had a higher use opioid and a lower treatment 
engagement when compared to the methadone treatment group. In total, both 
treatment groups had participant dropout which could be the result of a variety 
of issues from lack of support to low desired environments. Behavioral therapy 
treatments could help combat some of these issues being that counselors and 
psychologists not only provide skills to combat drug cravings but also assistance 
in daily life battles (Carroll et al., 2004). 
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The final study examined focused on patient perspectives of MATs and 
why buprenorphine was selected over methadone when both treatments were 
equally available. Many participants in the trial stated their preference for 
buprenorphine was due to the intense side effects that come with taking 
methadone (Gryczynski et al., 2013). The pharmacological health effects had the 
highest percentage rating for being very important to patients at 85% 
(Gryczynski et al., 2013). The main concern coming from patients was that 
methadone is physically dangerous and the withdrawal from methadone being 
significantly more difficult than buprenorphine (Gryczynski et al., 2013). Less 
important to the patients were the treatment delivery structure which shows that 
those looking for rehabilitation treatments prefer a better physical experience 
rather than convenience. 
41  
 
 
CONCLUSION 
 
 
Overall, combining a behavioral therapy treatment such as contingency 
management or cognitive behavioral therapy with a MAT such as buprenorphine 
or methadone is shown to increase treatment retention rates which leads to a 
greater success rate in opioid rehabilitation. When selecting a MAT, many 
aspects are considered such as the pharmacological effect that the drug will have 
on a person and past experiences had with the MAT either first or second hand. 
Continued efforts are needed to research additional behavioral therapies that can 
be combined with MATs to receive the most successful treatment. According to 
this review the most successful treatment option for opioid rehabilitation would 
be a behavioral therapy treatment combined with MAT using methadone. 
Undesired side effects may be present, but ultimately the success of methadone 
treatment in direct comparison to buprenorphine makes this the ultimate choice 
when striving for the best rehabilitation treatment outcome. 
. 
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